From: Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
Mutations (n = 168)a | n (%) |
---|---|
Sensitizing mutations | 157 (93.4) |
Common | 134 (79.8) |
Exon 19 (all mutations) | 96 (57.1) |
Exon 21 L858R | 38 (22.6) |
Rare | 23 (13.7) |
Exon 18 G719X | 10 (5.6) |
Exon 18 G719A | 3 (1.8) |
Exon 18 G719S | 3 (1.8) |
Exon 21 L861Q | 7 (4.2) |
Not sensitizing mutations | 7 (4.2) |
Exon 20 (all mutations) | 7 (4.2) |
Mutations of unknown significance | 4 (2.4) |
Exon 21 L858Q | 1 (0.6) |
Exon 21 E829Q | 1 (0.6) |
Exon 21 R836C | 1 (0.6) |
Exon 21 T854S | 1 (0.6) |